Castleman-TAFRO症候群研究会

31/03/2024

以下は医師向け文書です；
「特発性多中心性キャッスルマン病を対象としたフィルゴチニブ医師主導治験」のご案内

さて、現在、本院においてキャッスルマン病の患者様を対象とした医師主導治験を受託しております。参加可能な方の大まかな基準は以下の通りです。もし、該当する患者様がいらっしゃいましたら、ご紹介いただけますと幸いです。
なお、登録期間は2024年5月末までとなっております。時間的にも厳しい状況ですが、御協力賜われると幸いです。
敬具

【治験概略】
●フィルゴチニブ（200）　1回1錠、1日1回内服を8週間継続。
●来院回数は最大5回：スクリーニング・開始時・2週時・4週時・8週時
●継続パート試験あり：治験8週終了後、追加で44週間実施予定。

【ご参加いただける患者様の主な基準】
①18歳以上65歳未満の患者さん
②厚生労働省の特発性多中心性キャッスルマン病の診断基準を診断時に満たしている患者さん（病理学的所見が必要です）
③CRP ≧1（必須）かつヘモグロビン≦12.0またはアルブミン≦3.0を満たす活動性の患者さん
④腎機能が推定GFR ≧60を満たす患者さん
⑤ほかの全身性の自己免疫疾患を合併していない患者さん
現在トシリズマブやプレドニゾロンを使用している患者さんも対象としております(トシリズマブは4週の休薬期間が必要です。未治療症例も可能です)。

8週時点での安全性やCRPなどの改善をアウトカムとしております。その後、特定臨床研究として44週の合計52週の試験です。

こちらにお示しした以外にも細かな除外基準がありますので、詳細は正木康史までお問い合わせください。　yasum1macky1@gmail.com
ーーーーーーーーーーーーーーーーー
＊
本治験は、2024年4月26日をもって、予定登録症例数に達し、登録終了となりました。御協力誠にありがとうございました。

06/10/2022

第11回　キャッスルマン病患者会医療講演会

06/10/2022

キャッスルマン病患者会主催のWeb講演会を下記日程で開催いたします。
ご興味のある方は御聴講ください。
。

▼ Web(ZOOM)講演会
・主催：キャッスルマン病患者会
・日時：2022年11月5日（土）13:00～開場（添付パンフレット参照）
・内容：矢野先生、綾野先生、古賀先生、住吉先生にご講演いただくほか、正木先生、患者さんをお迎えしてパネルディスカッションを実施いたします。

▼ ZOOM情報（※事前申し込み不要です）
https://us02web.zoom.us/j/82253002024?pwd=a3luQnN2WmZIRWpzaTNVdEE4WWVxZz09
Join
our Cloud HD Video Meeting
Zoom
is the leader in modern enterprise video communications, with an easy, reliable cloud platform for video and audio conferencing, chat, and webinars across mobile, desktop, and room systems. Zoom Rooms is the original software-based conference room solution
used around the world in board, conference, huddle, and training rooms, as well as executive offices and classrooms. Founded in 2011, Zoom helps businesses and organizations bring their teams together in a frictionless environment to get more done. Zoom is
a publicly traded company headquartered in San Jose, CA.
us02web.zoom.us

ミーティングID: 822 5300 2024
パスコード: 845090

Zoom is the leader in modern enterprise video communications, with an easy, reliable cloud platform for video and audio conferencing, chat, and webinars across mobile, desktop, and room systems. Zoom Rooms is the original software-based conference room solution used around the world in board, confer...

27/02/2022

フジメディカル出版より待望の成書「キャッスルマン病，TAFRO症候群」が発刊されました。
Amazonなどでも注文できます。
https://www.amazon.co.jp/キャッスルマン病-TAFRO症候群-吉崎-和幸/dp/4862702503/ref=sr_1_2?__mk_ja_JP=カタカナ&crid=L9S3EIQQTUBN&keywords=キャッスルマン&qid=1646001734&sprefix=キャッスルマン%2Caps%2C205&sr=8-2

27/02/2022

文献（2022年に入ってからのもの）です。
新しい知見が少しずつ出てきました；
176. Masaki Y, Arita K, Sakai T, Takai K, Aoki S, Kawabata H. Castleman disease and TAFRO syndrome.Ann Hematol. 2022 Mar;101(3):485-490. doi: 10.1007/s00277-022-04762-6. Epub 2022 Jan 19.
177. Maisonobe L, Bertinchamp R, Damian L, Gérard L, Berisha M, Guillet S, Fieschi C, Malphettes M, Fadlallah J, Hié M, Dunogué B, De Wilde V, Vandergheynst F, Zafrani L, Grall M, Saada N, Garzaro M, Oksenhendler E, Galicier L, Boutboul D. Characteristics of thrombocytopenia, anasarca, fever, reticulin fibrosis and organomegaly syndrome: a retrospective study from a large Western cohort.Br J Haematol. 2022 Feb;196(3):599-605. doi: 10.1111/bjh.17868.
178. Godfrey K, Harris E, Moss H, Martin-Cabrera P. Idiopathic multicentric Castleman disease of TAFRO subtype. Br J Haematol. 2022 Feb;196(3):461. doi: 10.1111/bjh.17843.
179. Nagai M, Uchida T, Yamada M, Komatsu S, Ota K, Mukae M, Iwamoto H, Hirano H, Karube M, Kaname S, Oda T. TAFRO Syndrome in a Kidney Transplant Recipient That Was Diagnosed on Autopsy: A Case Report. Front Med (Lausanne). 2021 Oct 4;8:747678. doi: 10.3389/fmed.2021.747678. eCollection 2021.
180. Williams C, Phillips A, Aggarwal V, Slonim LB, Fajgenbaum DC, Karmali R. TAFRO Syndrome and Elusive Diagnosis of Idiopathic Multicentric Castleman Disease Treated with Empiric Anti-Interleukin-6 Therapy. Case Rep Oncol. 2021 Sep 21;14(3):1359-1365. doi: 10.1159/000518079. eCollection 2021 Sep-Dec.
181. Carbone A, Borok M, Damania B, Gloghini A, Polizzotto MN, Jayanthan RK, Fajgenbaum DC, Bower M. Castleman disease. Nat Rev Dis Primers. 2021 Nov 25;7(1):84. doi: 10.1038/s41572-021-00317-7.
182. Zhou T, Wang HW, Pittaluga S, Jaffe ES. Multicentric Castleman disease and the evolution of the concept. Pathologica. 2021 Oct;113(5):339-353. doi: 10.32074/1591-951X-351.
183. Uemura T, Matsui M, Kokubu M, Samejima KI, Tsuruya K. Renal histological continuum of TAFRO syndrome: A case report and literature review. Clin Nephrol. 2022 Feb;97(2):121-128. doi: 10.5414/CN110290.
184. Orrigio K, Jackson M, Fuller A, Ali Y, Avila L. Unilateral suprarenal hemorrhage in a teenager: A case of TAFRO. Pediatr Blood Cancer. 2021 Dec 6:e29475. doi: 10.1002/pbc.29475.
185. Abe N, Kono M, Kono M, Ohnishi N, Sato T, Tarumi M, Yoshimura M, Sato T, Karino K, Shimizu Y, Fujieda Y, Kato M, Hasebe R, Oku K, Murakami M, Atsumi T. Glycogen synthase kinase 3β/CCR6-positive bone marrow cells correlate with disease activity in multicentric Castleman disease-TAFRO. Br J Haematol. 2022 Mar;196(5):1194-1204. doi: 10.1111/bjh.17993. Epub 2021 Dec 6.
186. Otsuka Y, Shirakabe A, Asayama T, Okazaki H, Shibata Y, Shigihara S, Sawatani T, Yokose N, Asai K. Successful Treatment of Thrombocytopenia, Anasarca, Fever, Reticulin Myelofibrosis/Renal Insufficiency, and Organomegaly Syndrome Using Plasma Exchange Followed by Rituximab in the Intensive Care Unit. J Med Cases. 2021 Dec;12(12):474-480. doi: 10.14740/jmc3784. Epub 2021 Dec 2.
187. Shah N, Davidson T, Cheung C, Keung K. To and TAFRO - a cryptic cause of acute renal failure: a case report. BMC Nephrol. 2022 Jan 6;23(1):19. doi: 10.1186/s12882-022-02660-7.
188. Zhou B, Tang C, Chen G, Jiang T, Shi X, Wang F. TAFRO syndrome with fatigue and abdominal distension as the first symptom: A case report. Hematol Oncol. 2022 Jan 8. doi: 10.1002/hon.2962.
189. Hidekawa C, Yoshimi R, Kishimoto D, Kato H, Mitsuhashi M, Sakurai N, Sato Y, Uehara T, Iizuka Y, Komiya T, Hamada N, Nagai H, Soejima Y, Kamiyama R, Takase-Minegishi K, Kirino Y, Sakagami T, Nakajima H. Anti-interferon-γ Antibody-seropositive Disseminated Nontuberculous Mycobacterial Infection Mimicking POEMS and TAFRO Syndromes: A Case Report.Intern Med. 2022 Jan 13. doi: 10.2169/internalmedicine.8366-21.
190. Belyaeva E, Rubenstein A, Pierson SK, Dalldorf D, Frank D, Lim MS, Fajgenbaum DC. Bone marrow findings of idiopathic Multicentric Castleman disease: A histopathologic analysis and systematic literature review. Hematol Oncol. 2022 Feb 1. doi: 10.1002/hon.2969.
191. Osano K, Hanai S, Takahashi K, Furuya F. Glomeruloid Hemangioma in a Patient with TAFRO Syndrome. Intern Med. 2022 Feb 1. doi: 10.2169/internalmedicine.8888-21.
192. Yamagami K, Hanioka Y, Yao S, Nakamura R, Nakamura T, Ishii N, Goto H. A Case of TAFRO Syndrome Maintained in Remission for 5 Years After Discontinuation of Tocilizumab. Mod Rheumatol Case Rep. 2022 Feb 2:rxac007. doi: 10.1093/mrcr/rxac007.
193. Zhou QY. Castleman disease and TAFRO syndrome: To improve the diagnostic consciousness is the key. World J Clin Cases. 2022 Feb 16;10(5):1536-1547. doi: 10.12998/wjcc.v10.i5.1536.

27/02/2022

文献（2021年分追加）です；
153. Kawabata H, Fujimoto S, Sakai T, Yanagisawa H, Kitawaki T, Nara K, Hagihara M, Yamamoto H, Tanimizu M, Kato C, Origuchi T, Sunami K, Sunami Y, Masunari T, Nakamura N, Kobayashi M, Yamagami K, Miura K, Takai K, Aoki S, Tsukamoto N, Masaki Y. Correction to: Patient's age and D dimer levels predict the prognosis in patients with TAFRO syndrome. Int J Hematol. 2021 Aug;114(2):301-302. doi: 10.1007/s12185-021-03170-2.
154.Ono S, Yoshimoto K, Nishimura N, Yoneima R, Kawashima H, Kobayashi T, Tai Y, Miyamoto M, Tsushima E, Yada N, Nishio K. Complete Resolution of a Case of TAFRO Syndrome Accompanied by Mediastinal Panniculitis, Adrenal Lesion, and Liver Damage with Hyperbilirubinemia Intern Med. 2021 Apr 15;60(8):1303-1309.
155. Ide S, Ohara S, Uchida T, Inoue M, Hagihara M. [HHV-8-positive Castleman's disease with rapidly progressing multiorgan failure mimicking TAFRO syndrome]Rinsho Ketsueki. 2020;61(10):1497-1501. doi: 10.11406/rinketsu.61.1497.PMID: 33162447 Japanese.
156. Zhou Q, Zhang Y, Zhou G, Zhu J. Kidney biopsy findings in two patients with TAFRO syndrome: case presentations and review of the literature. BMC Nephrol. 2020 Nov 23;21(1):499. doi: 10.1186/s12882-020-02119-7.PMID: 33225930
157. Wakiya R, Kameda T, Takeuchi Y, Ozaki H, Nakashima S, Shimada H, Kadowaki N, Dobashi H. Sequential change in serum VEGF levels in a case of tocilizumab-resistant TAFRO syndrome treated effectively with rituximab.Mod Rheumatol Case Rep. 2021 Jan;5(1):145-151. doi: 10.1080/24725625.2020.1789304. Epub 2020 Jul 15.
158.Shibata S, Tabata S, Morita H, Endo T, Kawasaki N, Okamoto Y, Inano S, Takiuchi Y, Fukunaga A, Kitano T. Borderline Case of TAFRO Syndrome and POEMS Syndrome.Intern Med. 2021 May 15;60(10):1589-1595. doi: 10.2169/internalmedicine.5860-20. Epub 2020 Dec 15.
159. Minomo S, Fujiwara Y, Sakash*ta S, Takamura A, Nagata K. A severe case of thrombocytopenia, anasarca, fever, renal insufficiency or reticulin fibrosis, and organomegaly syndrome with myocardial and skeletal muscle calcification despite hypocalcemia: a case report.J Med Case Rep. 2021 Jan 6;15(1):3. doi: 10.1186/s13256-020-02588-2.
160. Killian M, Viel S, Chalayer E, Forest F, Grange S, Bonnefoy PB, Oksenhendler E, Cathébras P, Paul S. JAK1/2 Inhibition in Severe TAFRO Syndrome: A Case Report.Ann Intern Med. 2021 May;174(5):719-721. doi: 10.7326/L20-1051. Epub 2021 Jan 12.
161. Ohta T, Oda N, Saito K, Tamiya S, Ueno T. A Case of Repeated TAFRO Syndrome-Like Symptoms and Retroperitoneal Hemorrhage in a Patient With Sjögren Syndrome.Cureus. 2020 Dec 19;12(12):e12175. doi: 10.7759/cureus.12175.PMID: 33489586
162. Lanzillotta M, Sant'Angelo M, Kaneko N, Pillai S, Ponzoni M, Della-Torre E. Treating life-threatening TAFRO syndrome with interleukin-1 inhibition.Eur J Intern Med. 2021 May;87:121-123. doi: 10.1016/j.ejim.2021.02.006. Epub 2021 Feb 17.
163. Butzmann A, Kumar J, Sridhar K, Gollapudi S, Ohgami RS. A Review of Genetic Abnormalities in Unicentric and Multicentric Castleman Disease.Biology (Basel). 2021 Mar 24;10(4):251. doi: 10.3390/biology10040251.
164. Shimada K, Sasaki T, Okabe M, Koike K, Takahashi D, Terashima R, Honda Y, Matsumoto N, Fukui A, Ishikawa M, Tsuboi N, Yokoo T. TAFRO Syndrome With Kidney Involvement: A Case Series of Patients With Kidney Biopsies.Kidney Med. 2021 Jan 19;3(2):286-293. doi: 10.1016/j.xkme.2020.10.011. eCollection 2021 Mar-Apr.
165. Bhanvadia V, Shet T, Rao V, Epari S, Gujral S, Jain H, Bagal B, Sengar M. Multicentric Castleman's disease in India - Does EBV rather than HHV8 play a role? Indian J Pathol Microbiol. 2021 Apr-Jun;64(2):302-309. doi: 10.4103/IJPM.IJPM_310_20.
166. Nishioka H, Nishino S, Yoshizaki A, Hara S. TAFRO syndrome presenting as intrahepatic cholangitis on autopsy. Clin Case Rep. 2021 Mar 3;9(4):2254-2258. doi: 10.1002/ccr3.4005. eCollection 2021 Apr.
167. Okamoto T, Ochi S, Motokawa Y, Azumi H, Kobayashi S, Nakamura F, Nakatani T, Yagi H. Fatal case of TAFRO syndrome with unilateral adrenal hemorrhage in early-stage disease. J Clin Exp Hematop. 2021;61(2):109-113. doi: 10.3960/jslrt.20065.
168. Tu KH, Fan PY, Chen TD, Chuang WY, Wu CY, Ku CL, Tian YC, Yang CW, Fang JT, Yang HY. TAFRO Syndrome with Renal Thrombotic Microangiopathy: Insights into the Molecular Mechanism and Treatment Opportunities.Int J Mol Sci. 2021 Jun 11;22(12):6286. doi: 10.3390/ijms22126286.
169. Lust H, Gong S, Remiker A, Rossoff J. Idiopathic multicentric Castleman disease with TAFRO clinical subtype responsive to IL-6/JAK inhibition: A pediatric case series.Pediatr Blood Cancer. 2021 Oct;68(10):e29261. doi: 10.1002/pbc.29261. Epub 2021 Jul 24.
170. Lomas OC, Streetly M, Pratt G, Cavet J, Royston D, Schey S, Ramasamy K; British Society for Haematology (BSH) Committee. The management of Castleman disease. Br J Haematol. 2021 Nov;195(3):328-337. doi: 10.1111/bjh.17688. Epub 2021 Aug 2.
171. Yonezaki S, Nagasaki K, Yamaguchi H, Kobayashi H. Bilateral Adrenal Infarctions as an Initial Manifestation of TAFRO Syndrome: A Case Report and Review of the Literature. Intern Med. 2021 Aug 13. doi: 10.2169/internalmedicine.7976-21.
172. Fuentes-Lacouture MC, Gomez CC, Romero M, Borda A, Norena I, Naranjo JA. A Patient With Human Herpesvirus 8-Positive Multicentric Castleman's Disease Who Met Criteria for TAFRO Syndrome: Controversy in Practice? J Med Cases. 2020 Aug;11(8):253-255. doi: 10.14740/jmc3523. Epub 2020 Jul 21.
173. Hayashi M, Wada J, Fujita M, Asano T, Matsuoka N, Fujita Y, Temmoku J, Matsumoto H, Yashio-Furuya M, Sato S, Kobayashi H, Watanabe H, Ryoichiro K, Waragai Y, Suzuki E, Kiko Y, Abe K, Takahashi A, Masuda T, Hashimoto Y, Migita K, Ohira H. TAFRO syndrome complicated by porto-sinusoidal vascular liver disease with portal hypertension: a case report. Clin J Gastroenterol. 2021 Dec;14(6):1711-1717. doi: 10.1007/s12328-021-01515-2.
174. Sato H, Okada F, Baba H, Itaya T, Kashiwagi J, Asayama Y, Nawata T, Yamaguchi N, Suzuki T, Urabe S. A Case of TAFRO Syndrome With Pulmonary Abnormalities. J Thorac Imaging. 2021 Nov 1;36(6):W115-W117. doi: 10.1097/RTI.0000000000000616.
175. Akagi Y, Kato T, Yamash*ta Y, Hosoi H, Murata S, Yamamoto S, Warigaya K, Nakao T, Murata S, Sonoki T, Tamura S. Intracranial Hemorrhage in a Patient with TAFRO Syndrome Treated with Cyclosporine A and Rituximab. Medicina (Kaunas). 2021 Sep 16;57(9):971. doi: 10.3390/medicina57090971.

18/08/2021

第１回国際キャッスルマン病シンポジウムのオンデマンド配信が始まりました。
http://web.apollon.nta.co.jp/iscd2020/

非常に勉強になる講演が目白押しですので、ご興味のある方は是非ご覧ください。

国際シンポジウムですので、Dr.は3万円、Pt.は４千円とやや高めのRegistaration feeになっておりますが、期間内は何回でも視聴できます。

Venue: April 3 (Fri) » Geihinkan (9-1 Senri Expo Park, Suita City, Osaka 565-0826) April 4 (Sat)-5 (Sun) » Icho Kaikan (Osaka University Suita Campus) 2-2 Yamadaoka, Suita, Osaka 565-0871

25/10/2020

論文を追加します。
・135は後方視的治療研究のまとめで、治療の参考にしてください。
・136はTAFROの多数例の腎組織の検討で非常に重要です。
（We add further manuscripts. No.135 and No.136 are important articles.）

135. Fujimoto S, Kawabata H, Sakai T, Yanagisawa H, Nishikori M, Nara K, Ohara S, Tsukamoto N, Kurose N, Yamada S, Takai K, Aoki S, Masaki Y. Optimal treatments for TAFRO syndrome: a retrospective surveillance study in Japan. Int J Hematol. 2020 Sep 24. doi: 10.1007/s12185-020-03008-3.
136. Mizuno H, Sawa N, Watanabe S, Ikuma D, Sekine A, Kawada M, Yamanouchi M, Hasegawa E, Suwabe T, Hoshino J, Takaichi K, Kinowaki K, Fujii T, Ohashi K, Nagata M, Yamaguchi Y, Ubara Y. The Clinical and Histopathological Feature of Renal Manifestation of TAFRO Syndrome. Kidney Int Rep. 2020 May 19;5(8):1172-1179.
137 Dispenzieri A, Fajgenbaum DC. Overview of Castleman disease. Blood. 2020 Apr 16;135(16):1353-1364.
138. Fujikawa H, Araki M. TAFRO syndrome. Balkan Med J. 2020 Aug 11;37(5):293-294.
139. Ducoux G, Guerber A, Durel CA, Asli B, Fadlallah J, Hot A. Thrombocytopenia, Anasarca, Fever, Reticulin Fibrosis/Renal Failure, and Organomegaly (TAFRO) Syndrome with Bilateral Adrenal Hemorrhage in Two Caucasian Patients. Am J Case Rep. 2020 Apr 6;21:e919536. doi: 10.12659/AJCR.919536.
140. Pai RL, Japp AS, Gonzalez M, Rasheed RF, Okumura M, Arenas D, Pierson SK, Powers V, Layman AAK, Kao C, Hakonarson H, van Rhee F, Betts MR, Kambayashi T, Fajgenbaum DC. Type I IFN response associated with mTOR activation in the TAFRO subtype of idiopathic multicentric Castleman disease. Am J Case Rep. 2020 Apr 6;21:e919536. doi: 10.12659/AJCR.919536.
141. Kobayashi S, Inui A, Tsunoda T, Umetsu S, Sogo T, Mori M, Shinkai M, Fujisawa T. Liver cirrhosis in a child associated with Castleman's disease: A case report. World J Clin Cases. 2020 May 6;8(9):1656-1665.
142. Xia P, Zhang L, Zou M, Zhang T, Li R, Shi X, Wang J, Qin Y, Li X, Li J, Chen L. Acute Kidney Injury Caused by TAFRO Syndrome in a Chinese Patient: Efficacy of Long-Term Corticosteroids Combined with Bortezomib and Cyclophosphamide. Kidney Blood Press Res. 2020;45(4):623-630.
143. Marchetti M, Feyles E, Zinzani P. Frontline Siltuximab and Rituximab in TAFRO syndrome: A case report. Eur J Haematol. 2020 Jun 21. doi: 10.1111/ejh.13473.
144. Minamikawa S, Matsumura O, Sato S, Nakagishi Y, Tanaka R. A pediatric case of tocilizumab-resistant TAFRO syndrome treated successfully with rituximab. Pediatr Blood Cancer. 2020 Dec;67(12):e28489. doi: 10.1002/pbc.28489.
145. Simeni Njonnou SR, Deuson J, Royer-Chardon C, Vandergheynst FA, Wilde V. Unexplained cause of thrombocytopenia, fever, anasarca and hypothyroidism: TAFRO syndrome with thrombotic microangiopathy renal histology. BMJ Case Rep. 2020 Jun 30;13(6):e234155. doi: 10.1136/bcr-2019-234155.
146. Abbass A, Khalid S, Toth L, Eberhardt S, McCarthy D. Ascites in the "TAFRO" Syndrome: Does the Squeeze Make the Juice? Dig Dis Sci. 2020 Sep;65(9):2522-2526.
147. Oka K, Yamane M, Yokota Y, Yasuda M, Hasegawa K, Fujimori T, Iio K, Hagiya H, Otsuka F. Disseminated Mycobacterium genavense infection mimicking TAFRO syndrome. J Infect Chemother. 2020 Oct;26(10):1095-1099.
148. Akiyama M, Kaneko Y, Takeuchi T. Tocilizumab for the treatment of TAFRO syndrome: a systematic literature review. Ann Hematol. 2020 Nov;99(11):2463-2475.
149. Suzuki E, Ichimura T, Kimura S, Kanno T, Migita K. Primary Sjögren's Syndrome Accompanied by Clinical Features of TAFRO Syndrome. Case Rep Rheumatol. 2020 Sep 17;2020:8872774. doi: 10.1155/2020/8872774. eCollection 2020
150. Wada M, Nagata A, Kawashima A, Kagawa K. An Autopsy Case of TAFRO Syndrome with Type II Respiratory Failure. Am J Case Rep. 2020 Oct 13;21:e926721. doi: 10.12659/AJCR.926721.
151. Kadoba K, Waki D, Nishimura K, Mukoyama H, Saito R, Murabe H, Yokota T. Development of severe thrombocytopenia with TAFRO syndrome-like features in a patient with rheumatoid arthritis treated with a Janus kinase inhibitor: A case report. Medicine (Baltimore). 2020 Oct 16;99(42):e22793. doi: 10.1097/MD.0000000000022793
152. Yamaguchi Y, Maeda Y, Shibahara T, Nameki S, Nakabayashi A, Komuta K, Mizuno Y, Yagita M, Manabe Y, Morita T, Nishide M, Watanabe A, Takamatsu H, Nishida S, Hirano T, Shima Y, Narazaki M, Kumanogoh A. Recovery from prolonged thrombocytopenia in patients with TAFRO syndrome: case series and literature review. Mod Rheumatol Case Rep. 2020 Jul;4(2):302-309.

01/06/2020

論文を追加します（We add further articles.）
119. Kageyama C, Igawa T, Gion Y, Iwaki N, Tabata T, Tanaka T, Kondo E, Sakai H, Tsuneyama K, Nomoto K, Noguchi H, Yoshino T, Yokota K, Sato Y. Hepatic Campylobacter jejuni infection in patients with Castleman‐Kojima disease (idiopathic multicentric Castleman disease with thrombocytopenia, anasarca, fever, reticulin fibrosis, and organomegaly (TAFRO) syndrome). Pathol Int. 2019 Oct;69(10):572-579. doi: 10.1111/pin.12856.
120. Nagayama Y, Yamano M, Yagame M, Nariyama T, Takahashi M, Kawamoto M, Matsui K. TAFRO syndrome as a cause of glomerular microangiopathy: a case report and literature review. BMC Nephrol. 2019 Oct 17;20(1):375. doi: 10.1186/s12882-019-1574-9.
121. Matsuhisa T, Takahashi N, Nakaguro M, Sato M, Inoue E, Teshigawara S, Ozawa Y, Kondo T, Nakamura S, Sato J, Ban N. Fatal case of TAFRO syndrome associated with over-immunosuppression: a case report and review of the literature. Nagoya J Med Sci. 2019 Aug;81(3):519-528. doi: 10.18999/nagjms.81.3.519.
122. Miatech JL, Patel NR, Latuso NQ, Ellipeddi PK. TAFRO Syndrome: A Case of Significant Endocrinopathy in a Caucasian Patient. Cureus. 2019 Jun 19;11(6):e4946. doi: 10.7759/cureus.4946.
123. Fajgenbaum DC, Langan RA, Japp AS, Partridge HL, Pierson SK, Singh A, Arenas DJ, Ruth JR, Nabel CS, Stone K, Okumura M, Schwarer A, Jose FF, Hamerschlak N, Wertheim GB, Jordan MB, Cohen AD, Krymskaya V, Rubenstein A, Betts MR, Kambayashi T, van Rhee F, Uldrick TS. Identifying and targeting pathogenic PI3K/AKT/mTOR signaling in IL-6-blockade-refractory idiopathic multicentric Castleman disease. J Clin Invest. 2019 Aug 13;130:4451-4463. doi: 10.1172/JCI126091.
124. Masaki Y, Kawabata H, Fujimoto S, Kawano M, Iwaki N, Kotani T, Nakashima A, Kurose N, Takai K, Suzuki R, Aoki S. Epidemiological Analysis of Multicentric and Unicentric Castleman Disease and TAFRO Syndrome in Japan. J Clin Exp Hematop. 2019 Dec 22;59(4):175-178. doi: 10.3960/jslrt.19021. Epub 2019 Nov 8.
125. Masaki Y, Kawabata H, Takai K, Tsukamoto N, Fujimoto S, Ishigaki Y, Kurose N, Miura K, Nakamura S, Aoki S; Japanese TAFRO Syndrome Research Team. 2019 Updated Diagnostic Criteria and Disease Severity Classification for TAFRO Syndrome. Int J Hematol. 2020 Jan;111(1):155-158. doi: 10.1007/s12185-019-02780-1. Epub 2019 Nov 28.
126. Yanagiya R, Suzuki T, Nakamura S, Fujita K, Oyama M, Okuyama A, Sugasawa K, Nakayama T, Suzuki Y, Ishizawa K, Saito S. TAFRO Syndrome Presenting With Retroperitoneal Panniculitis-like Computed Tomography Findings at Disease Onset. Intern Med. 2020 Apr 1;59(7):997-1000. doi: 10.2169/internalmedicine.3740-19. Epub 2019 Dec 13.
127. Li ZY, Kim S, Huang S, Mian R. Multicentric Castleman Disease With TAFRO Syndrome and Sjögren's. Clin Case Rep. 2019 Oct 24;7(12):2388-2392. doi: 10.1002/ccr3.2502. eCollection 2019 Dec.
128. Zhang Y, Suo SS, Yang HJ, Zhou XP, You LS, Yu WJ, Wang ZM, Jin J. Clinical Features and Treatment of 7 Chinese TAFRO Syndromes From 96 De Novo Castleman Diseases: A 10-year Retrospective Study. J Cancer Res Clin Oncol. 2020 Feb;146(2):357-365. doi: 10.1007/s00432-019-03120-w. Epub 2020 Jan 14.
129. Yoshimi A, Trippett TM, Zhang N, Chen X, Penson AV, Arcila ME, Pichardo J, Baik J, Sigler A, Harada H, Fajgenbaum DC, Dogan A, Abdel-Wahab O, Xiao W. Genetic Basis for iMCD-TAFRO. Oncogene. 2020 Apr;39(15):3218-3225. doi: 10.1038/s41388-020-1204-9. Epub 2020 Feb 12.
130. Fujikawa H, Araki M. TAFRO Syndrome. Balkan Med J. 2020 Mar 25. doi: 10.4274/balkanmedj.galenos.2020.2020.3.30.
131. Ducoux G, Guerber A, Durel CA, Asli B, Fadlallah J, Hot A. Thrombocytopenia, Anasarca, Fever, Reticulin Fibrosis/Renal Failure, and Organomegaly (TAFRO) Syndrome With Bilateral Adrenal Hemorrhage in Two Caucasian Patients. Am J Case Rep. 2020 Apr 6;21:e919536. doi: 10.12659/AJCR.919536.
132. Pai RL, Japp AS, Gonzalez M, Rasheed RF, Okumura M, Arenas D, Pierson SK, Powers V, Layman AAK, Kao C, Hakonarson H, van Rhee F, Betts MR, Kambayashi T, Fajgenbaum DC. Type I IFN Response Associated With mTOR Activation in the TAFRO Subtype of Idiopathic Multicentric Castleman Disease. JCI Insight. 2020 May 7;5(9):135031. doi: 10.1172/jci.insight.135031.
133. Kobayashi S, Inui A, Tsunoda T, Umetsu S, Sogo T, Mori M, Shinkai M, Fujisawa T. Liver Cirrhosis in a Child Associated With Castleman's Disease: A Case Report. World J Clin Cases. 2020 May 6;8(9):1656-1665. doi: 10.12998/wjcc.v8.i9.1656.
134. Kurokawa R, Gonoi W, Yokota H, Isshiki S, Ohira K, Mizuno H, Kiguchi T, Inui S, Kurokawa M, Kato S, Matsuki M, Takeda T, Yokoyama K, Ota Y, Nakai Y, Maeda E, Mori H, Abe O. Computed Tomography Findings of Early-Stage TAFRO Syndrome and Associated Adrenal Abnormalities. Eur Radiol. 2020 May 21. doi: 10.1007/s00330-020-06919-1. Online ahead of print.

06/01/2020

TAFRO症候群およびCastleman病の疫学研究の論文が掲載されました。
Epidemiological analysis of multicentric and unicentric Castleman disease and TAFRO syndrome in Japan has been published.

Japan's largest platform for academic e-journals: J-STAGE is a full text database for reviewed academic papers published by Japanese societies

05/01/2020

TAFRO症候群の診断基準・重症度分類2019マイナー改訂の論文（Letter）が掲載されました。
2019 Updated diagnostic criteria and disease severity classification for TAFRO syndrome has been published.
Int J Hematol. 111(1), 155-158.. doi: 10.1007/s12185-019-02780-1.

Letter to the Editor Published: 28 November 2019 2019 Updated diagnostic criteria and disease severity classification for TAFRO syndrome Yasufumi Masaki ORCID: orcid.org/0000-0002-5658-37651, Hiroshi Kawabata1, Kazue Takai2, Norifumi Tsukamoto3, Shino Fujimoto1, Yasuhito Ishigaki4, Nozomu Kurose5, K...

04/08/2019

更に論文を追加します（We add further articles.）

116. Fujimoto S, Sakai T, Kawabata H, Kurose N, Yamada S, Takai K, Aoki S, Kuroda J, Ide M, Setoguchi K, Tsukamoto N, Iwao-Kawanami H, Kawanami T, Mizuta S, Fukushima T, Masaki Y. Is TAFRO syndrome a subtype of idiopathic multicentric Castleman disease? Am J Hematol. 2019 Jun 10. doi: 10.1002/ajh.25554.
117. Kurose N, Guo X, Shioya A, Mizutani KI, Kumagai M, Fujimoto S, Kawabata H, Masaki Y, Takai K, Aoki S, Nakamura S, Yamada S. The potential role of follicular helper T cells in idiopathic multicentric Castleman disease with and without TAFRO syndrome. Pathol Res Pract. 2019 Jul 26:152563. doi: 10.1016/j.prp.2019.152563.
118. Kurose N, Mizutani KI, Kumagai M, Shioya A, Guo X, Nakada S, Fujimoto S, Kawabata H, Masaki Y, Takai K, Aoki S, Kojima M, Nakamura S, Kida M, Yamada S. An extranodal histopathological analysis of idiopathic multicentric Castleman disease with and without TAFRO syndrome. Pathol Res Pract. 2019 Mar;215(3):410-413. doi: 10.1016/j.prp.2018.12.025. Epub 2018 Dec 26.